Taxonomic position, antibiotic resistance and virulence factors of clinical Achromobacter isolates.

Frontiers in bioscience (Scholar edition) Pub Date : 2022-03-21 DOI:10.31083/j.fbs1402009

Ad C Fluit, Jumamurat R Bayjanov, María Díez Aguilar, Barry Benaissa-Trouw, Michael M Tunney, Mireille van Westreenen, Jacques F Meis, J Stuart Elborn, Rafael Cantón, Miquel B Ekkelenkamp

{"title":"Taxonomic position, antibiotic resistance and virulence factors of clinical Achromobacter isolates.","authors":"Ad C Fluit, Jumamurat R Bayjanov, María Díez Aguilar, Barry Benaissa-Trouw, Michael M Tunney, Mireille van Westreenen, Jacques F Meis, J Stuart Elborn, Rafael Cantón, Miquel B Ekkelenkamp","doi":"10.31083/j.fbs1402009","DOIUrl":null,"url":null,"abstract":"The role of Achromobacter species in lung disease remains unclear. The aim of this study was to characterize Achromobacter isolated from persons with cystic fibrosis and from other clinical samples. Whole genome sequences from 101 Achromobacter isolates were determined (81 from patients with cystic fibrosis and 20 from other patients) and analysed. Taxonomic analysis showed nine species including two putative novel species. Thirty-five novel sequence types were present. The most active agent was co-trimoxazole followed by imipenem, but Minimal Inhibitory Concentrations (MICs) were high. Acquired antibiotic resistance genes were rare. Their presence did not correlate with minimal inhibitory concentrations suggesting that other mechanisms are involved. Genes for proposed virulence factors were present in only some isolates. Two putative novel species were identified. The putative virulence properties of Achromobacter involved in infections are variable. Despite the high MICs, acquired resistance genes are uncommon.","PeriodicalId":73070,"journal":{"name":"Frontiers in bioscience (Scholar edition)","volume":"14 2","pages":"9"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in bioscience (Scholar edition)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31083/j.fbs1402009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The role of Achromobacter species in lung disease remains unclear. The aim of this study was to characterize Achromobacter isolated from persons with cystic fibrosis and from other clinical samples. Whole genome sequences from 101 Achromobacter isolates were determined (81 from patients with cystic fibrosis and 20 from other patients) and analysed. Taxonomic analysis showed nine species including two putative novel species. Thirty-five novel sequence types were present. The most active agent was co-trimoxazole followed by imipenem, but Minimal Inhibitory Concentrations (MICs) were high. Acquired antibiotic resistance genes were rare. Their presence did not correlate with minimal inhibitory concentrations suggesting that other mechanisms are involved. Genes for proposed virulence factors were present in only some isolates. Two putative novel species were identified. The putative virulence properties of Achromobacter involved in infections are variable. Despite the high MICs, acquired resistance genes are uncommon.

查看原文本刊更多论文

临床分离无色杆菌的分类位置、耐药性及毒力因素。

无色杆菌在肺部疾病中的作用尚不清楚。本研究的目的是表征从囊性纤维化患者和其他临床样本中分离的无色杆菌。对101株无色杆菌分离株(81株来自囊性纤维化患者，20株来自其他患者)的全基因组序列进行了测定和分析。分类分析发现9种，其中2种推定为新种。发现35种新的序列类型。活性最强的药物是复方新诺明，其次是亚胺培南，但最低抑菌浓度(mic)较高。获得性抗生素耐药基因罕见。它们的存在与最低抑制浓度无关，这表明涉及其他机制。所提出的毒力因子基因仅在部分分离株中存在。鉴定出两个假定的新种。参与感染的无色杆菌的假定毒力特性是可变的。尽管mic很高，但获得性耐药基因并不常见。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in bioscience (Scholar edition)

自引率

0.00%

发文量